Eamonn Molloy, M.D.
| Appointed: |
2008 |
| Gender: |
Male |
| Languages: |
English |
Rheumatologic and Immunologic Disease
Biographical Sketch
Other publications:
- Molloy E, Ramakrishnan S, Murphy E, Barry M. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. Rheumatology 2004; 43: 522-3.
- Molloy E, Cahill M, O’Hare JA. Cerebral venous sinus thrombosis precipitated by Graves’ disease and factor V Leiden mutation. Ir Med J 2003; 96(2): 46-7.
- Molloy E, O’Hare JA. Unraveling medical outpatient referrals. Ir Med J 2003; 96(5): 145-6.
- Molloy E, Clarke D, Fearon U, Cunningham SK, McKenna TJ. Non-ACTH pro-opiomelanocortin fragments stimulate aldosterone production by human adrenal cells in vitro. Steroids 1998; 63(9): 459-463
Education & Fellowships
| Medical School: | University College Dublin (National University of Ireland), Dublin, Ireland |
|
| Internship: | Saint Vincent's University Hospital, Internal Medicine, Dublin 4, Ireland, Ireland |
| Residency: | James Connolly Memorial Hospital, Rheumatology & Internal Medicine, Ir |
| Residency: | Mater Misericordiae University Hospital, Dublin, Ireland |
| Residency: | Limerick Regional Hospital, Internal Medicine/Endocrinology and diabetes |
| Residency: | Mater Misericordiae University Hospital, Internal Medicine, Dublin, Ireland |
| Fellowship: | Royal College of Physicians of Ireland, Rheumatology Specialist Registrar Program, Ireland |
| Fellowship: | Cleveland Clinic, Vasculitis, Cleveland, OH |
| Other Education: | (Research Fellowship) Cleveland Clinic, Cleveland, OH |
Certifications
Royal College of Physicians of Ireland - Internal Medicine
Royal College of Surgeons of Ireland
Specialty Interests
Clinical immunology, vasculitis, systemic autoimmune diseases, lupus, crystal arthritis. hypogammaglobulinemia.
Specializes in Diseases and Conditions
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 10/24/2008 the review process regarding Dr. Molloy’s disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
